share_log

Clearmind Medicine | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

SEC announcement ·  Mar 20 16:58
Summary by Moomoo AI
Clearmind Medicine Inc. (CMND), a pharmaceutical company specializing in the development of psychedelic medicines, has filed a post-effective amendment to its Form F-1 registration statement with the Securities and Exchange Commission (SEC) on March 20, 2024. The amendment pertains to the registration of 1,500,000 common shares, which are issuable upon the exercise of warrants originally issued in a private placement on January 16, 2024. The registration statement, initially filed on February 7, 2024, and declared effective by the SEC on February 16, 2024, covered the resale of common shares by the Selling Shareholder. This amendment is intended to update and supplement information contained in the original registration statement and to include updated financial information. No additional securities are being registered under this amendment, which solely concerns the sale...Show More
Clearmind Medicine Inc. (CMND), a pharmaceutical company specializing in the development of psychedelic medicines, has filed a post-effective amendment to its Form F-1 registration statement with the Securities and Exchange Commission (SEC) on March 20, 2024. The amendment pertains to the registration of 1,500,000 common shares, which are issuable upon the exercise of warrants originally issued in a private placement on January 16, 2024. The registration statement, initially filed on February 7, 2024, and declared effective by the SEC on February 16, 2024, covered the resale of common shares by the Selling Shareholder. This amendment is intended to update and supplement information contained in the original registration statement and to include updated financial information. No additional securities are being registered under this amendment, which solely concerns the sale of common shares by the Selling Shareholders. The selling shareholders may not sell these securities until the registration statement filed with the SEC is effective. The preliminary prospectus, dated March 20, 2024, relates to the resale of up to 1,500,000 common shares by the selling shareholders, with Clearmind Medicine not receiving any proceeds from the sale. The common shares are traded on the Nasdaq Capital Market under the symbol 'CMND' and on the Frankfurt Stock Exchange under the symbol 'CWY'.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more